Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Astermark

Showing results (41-50 of 92) with videos related to

Pageof 10
Sort By:
Research and Practice in Thrombosis and Haemostasis|December 10, 2025
Evaluation of kidney function and damage in patients with hemophilia B-insights from the B-Natural studyJan Astermark, Petra LeBeau, Anders Christensson, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 9, 2021
Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia AJan Astermark, Anna Olsson, Pierre Chelle, et al.
Therapeutic Advances in Hematology|April 28, 2023
Considerations for shared decision management in previously untreated patients with hemophilia A or BJan Astermark, Jan Blatný, Christoph Königs, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 11, 2021
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnairesJan Astermark, Cédric Hermans, Monia Ezzalfani, et al.
Blood|August 24, 2006
Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia AJan Astermark, Johannes Oldenburg, Joyce Carlson, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 15, 2019
Joint comorbidities among Swedish carriers of haemophilia: A register-based cohort study over 22 yearsMehdi Osooli, Sharyne M Donfield, Katarina Steen Carlsson, et al.
Therapeutic Advances in Hematology|June 7, 2023
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: Jan Astermark, Cédric Hermans, Monia Ezzalfani, et al.
Blood|September 23, 2006
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) StudyJan Astermark, Sharyne M Donfield, Donna M DiMichele, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 29, 2019
Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia: A comparison between intermediate- and high-dose prophylaxisOlav Versloot, Erik Berntorp, Pia Petrini, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 17, 2021
Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?Katharina Holstein, Sandra Le Quellec, Robert Klamroth, et al.
Pageof 10

Showing results (41-50 of 92) with videos related to

Sort By:
Pageof 10
Research and Practice in Thrombosis and Haemostasis|December 10, 2025
Evaluation of kidney function and damage in patients with hemophilia B-insights from the B-Natural studyJan Astermark, Petra LeBeau, Anders Christensson, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 9, 2021
Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia AJan Astermark, Anna Olsson, Pierre Chelle, et al.
Therapeutic Advances in Hematology|April 28, 2023
Considerations for shared decision management in previously untreated patients with hemophilia A or BJan Astermark, Jan Blatný, Christoph Königs, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 11, 2021
rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnairesJan Astermark, Cédric Hermans, Monia Ezzalfani, et al.
Blood|August 24, 2006
Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia AJan Astermark, Johannes Oldenburg, Joyce Carlson, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 15, 2019
Joint comorbidities among Swedish carriers of haemophilia: A register-based cohort study over 22 yearsMehdi Osooli, Sharyne M Donfield, Katarina Steen Carlsson, et al.
Therapeutic Advances in Hematology|June 7, 2023
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: Jan Astermark, Cédric Hermans, Monia Ezzalfani, et al.
Blood|September 23, 2006
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) StudyJan Astermark, Sharyne M Donfield, Donna M DiMichele, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 29, 2019
Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia: A comparison between intermediate- and high-dose prophylaxisOlav Versloot, Erik Berntorp, Pia Petrini, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|December 17, 2021
Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?Katharina Holstein, Sandra Le Quellec, Robert Klamroth, et al.
Pageof 10